NCT05990985 - The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

August 1, 2024

Study Completion Date

August 1, 2026

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG

Mitoxantrone hydrochloride liposome injection

Mitoxantrone hydrochloride liposome injection (18 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.

DRUG

RiTUXimab Injection

RiTUXimab Injection (375 mg/m\^2) will be administered by intravenous infusion on day 0 in a 3-week treatment cycle.

DRUG

Cyclophosphamid

Cyclophosphamid (750 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.

DRUG

Vincristine

Vincristine (1.4 mg/m\^2，maximum dose 2mg ) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.

DRUG

Prednisolone

Prednisolone (100mg/d) will be administered by intravenous infusion on day 1-5 in a 3-week treatment cycle.

Trial Locations (1)

The First Bethune Hospital of Jilin University, Changchun